Reference is made to the merger between Aker BioMarine ASA (the "Aker
BioMarine") and Aker Capital NewCo AS ("MergerCo"), an indirect wholly-owned
subsidiary of Aker ASA announced on 16 July 2026 and approved by an
extraordinary general meeting of Aker BioMarine on 17 August 2026 (the
"Merger").
The creditor notice period for the Merger has now expired and all conditions for
completion of the merger are fulfilled.
The merger is expected to be completed after close of trading on 1 October 2026.
Key dates and information for the completion of the Merger will then be as
follows:
- Last day of trading in Aker BioMarine shares on Euronext Oslo Børs (and last
day of trading inclusive of right to merger consideration): 1 October 2026
- Effective date for completion of the Merger: 1 October 2026 (after close of
trade)
- Record date for delivery of merger consideration to former Aker BioMarine
shareholders: 5 October 2026
- Delivery of consideration shares to former Aker BioMarine shareholders: 6
October 2026
- Payment of cash consideration to former Aker BioMarine shareholders: 7 October
2026
- Transferor company: Aker BioMarine ASA
- Transferee company: Aker Capital NewCo AS, with consideration shares delivered
by Aker ASA
- Merger consideration: Aker BioMarine shareholders will for each Aker BioMarine
share held per the record date receive 0.0706 shares in Aker ASA plus a cash
amount of NOK 21 per share
- Date of approvals: 17 August 2026 (extraordinary general meetings)
- Additional information: Fractions of Aker consideration shares will not be
allotted in the Merger. For each Aker BioMarine shareholder the number of Aker
shares will be rounded down to each whole number, or to zero shares. Excess
shares, which because of this round down will not be allotted to eligible
shareholders, will be issued to and sold by an appointed investment bank or
other third party according to instructions from Aker at the expense and risk of
the beneficiaries with a proportionate distribution of net sales proceeds among
the shareholders who have the number of consideration shares rounded off.
For further information on the Merger and the complete terms and conditions for
the Merger, please see the merger plan for the Merger available on:
www.akerasa.com and akerbiomarine.com.
This information has been submitted pursuant to section 5-12 of the Norwegian
Securities Trading Act.
nt to section 5-12 of the Norwegian\
Securities Trading Act.\